首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗開發業務受託機關

臨床前CRO市場規模、佔有率和成長分析（按服務、模式、應用、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1903209

臨床前CRO市場規模、佔有率和成長分析（按服務、模式、應用、最終用戶和地區分類）－2026-2033年產業預測

Preclinical CRO Market Size, Share, and Growth Analysis, By Service (Bioanalysis and DMPK studies, Toxicology Testing), By Model, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球非臨床 CRO 市場規模預計在 2024 年達到 70.1 億美元，從 2025 年的 76.9 億美元成長到 2033 年的 160.1 億美元，在預測期（2026-2033 年）內複合年成長率為 9.6%。

全球臨床前CRO（受託研究機構）市場正經歷顯著成長，這主要得益於生物製藥公司、醫療設備製造商和政府機構對CRO服務需求的不斷成長。慢性病和遺傳性疾病發生率的上升促使這些機構加強對創新藥物和診斷設備的研發投入。將臨床前研究外包給CRO，使企業能夠專注於自身核心競爭力，同時獲得專業支援以提升研發能力。此外，開發救命藥物的緊迫性使得臨床前CRO在藥物開發和商業化策略中扮演著至關重要的角色，這提升了它們在不斷發展的生物製藥行業中的重要性，並推動了市場擴張。

全球臨床前CRO市場促進因素

臨床前CRO服務的擴張主要受生物製藥產業的快速發展所驅動。隨著生物製藥公司不斷拓展創新治療方法的研發領域，它們擴大將關鍵的臨床前研究（包括療效和毒性評估）外包給CRO。隨著企業在加速複雜藥物研發的同時最佳化資源和專業知識，這種外包趨勢預計將在未來推動對臨床前CRO服務的需求。因此，對CRO日益成長的依賴預計將推動臨床前市場領域的成長。

限制全球臨床前CRO市場的因素

全球臨床前CRO市場的主要限制因素之一源自於臨床前研究外包帶來的挑戰。生物製藥公司在使用第三方CRO時，會放棄對研發過程的部分監管權。這種控制權的喪失會導致延誤、溝通不良和結果不一致，從而阻礙研發進度。因此，這種依賴性會阻礙高效率的研發，並影響藥物研發的整體品質和進度。與第三方機構保持有效的協作和溝通至關重要，但卻難以實現，最終會影響該領域的創新和進步。

全球臨床前CRO市場趨勢

全球臨床前CRO市場正經歷自動化和人工智慧（AI）融合的顯著趨勢，這從根本上重塑了其營運方式。這種變革提高了研究效率和準確性，從而縮短了研發週期並顯著降低了成本。人工智慧驅動的解決方案正在最佳化數據處理、預測建模和藥物開發，使企業能夠在保持高品質標準的同時更快地交付成果。隨著這些技術的應用日益廣泛，臨床前CRO產業預計將持續轉型。相關人員將越來越依賴先進的分析技術和自動化來簡化工作流程，並在整個藥物開發過程中提高生產力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Charles River Laboratories International, Inc.（USA）
Labcorp Drug Development（USA）
Eurofins Scientific（Luxembourg）
ICON plc（Ireland）
IQVIA（USA）
Parexel International Corporation（USA）
PPD（USA）
Syneos Health（USA）
Crown Bioscience（USA）
Envigo（USA）
Intertek Group plc（UK）
SGS SA（Switzerland）
MPI Research（USA）
Worldwide Clinical Trials（USA）
Inotiv, Inc.（USA）
Jubilant Biosys Ltd.（India）

結論與建議

簡介目錄

Product Code: SQMIG35D2298

Global Preclinical CRO Market size was valued at USD 7.01 Billion in 2024 and is poised to grow from USD 7.69 Billion in 2025 to USD 16.01 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global preclinical Contract Research Organization (CRO) market is experiencing significant growth, driven by the increasing demand from biopharmaceutical companies, medical device firms, and government agencies that utilize CRO services. The rising incidence of chronic illnesses and genetic disorders has prompted these organizations to invest extensively in research for innovative drugs and diagnostic devices. By outsourcing preclinical research to CROs, companies can concentrate on their primary activities while receiving specialized support that enhances their research and development capabilities. Furthermore, the urgent need for the creation of life-saving medications positions preclinical CROs as vital players in drug development and commercialization strategies, reinforcing their importance in the evolving biopharmaceutical landscape and propelling market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preclinical CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preclinical CRO Market Segments Analysis

Global Preclinical CRO Market is segmented by Service, Model, Application, End User and region. Based on Service, the market is segmented into Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology and Others. Based on Model, the market is segmented into Patient-Derived Organoid (PDO) Model and Patient-Derived Xenograft Model. Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnological Companies, Government and Academic Institutes, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Preclinical CRO Market

A significant catalyst for the expansion of preclinical Contract Research Organization (CRO) services is the swift advancement of the biopharmaceutical industry. As biopharmaceutical companies increasingly venture into the development of innovative therapies, they are turning to CROs for essential preclinical testing, including drug efficacy and toxicity assessments. This tendency towards outsourcing is expected to drive future demand for preclinical CRO services, as firms seek to optimize their resources and expertise while navigating the complexities of drug development. Consequently, the reliance on CROs is anticipated to bolster growth within the preclinical segment of the market.

Restraints in the Global Preclinical CRO Market

One significant constraint in the Global Preclinical CRO market stems from the challenges associated with outsourcing preclinical testing. When biopharmaceutical companies engage third-party CROs, they may relinquish some degree of oversight over the development processes. This loss of control can hinder progress, as it often results in delays, miscommunication, and inconsistent outcomes. Consequently, such dependencies create obstacles to efficient research and may impact the overall quality and timelines of drug development. The ability to maintain effective collaboration and communication with third-party entities is critical, yet can be difficult to achieve, ultimately affecting innovation and advancement in the field.

Market Trends of the Global Preclinical CRO Market

The Global Preclinical CRO market is witnessing a significant trend towards the integration of automation and artificial intelligence (AI), fundamentally reshaping operational methodologies. This evolution enhances research efficiency and accuracy, leading to expedited timelines and substantial cost savings. AI-driven solutions are optimizing data processing, predictive modeling, and drug development, enabling companies to deliver results more quickly while maintaining high-quality standards. As these technologies are increasingly adopted, the preclinical CRO sector is expected to experience a continuous transformation, with stakeholders increasingly relying on advanced analytics and automation to streamline workflows and improve overall productivity in the drug development journey.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Preclinical CRO Market Size by Service & CAGR (2026-2033)

Market Overview
Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK
Toxicology Testing
- GLP
- Non-GLP
Compound Management
- Process R&D
- Custom Synthesis
- Others
Chemistry
- Medicinal Chemistry
- Computation Chemistry
Safety Pharmacology
Others

Global Preclinical CRO Market Size by Model & CAGR (2026-2033)

Market Overview
Patient-Derived Organoid (PDO) Model
Patient-Derived Xenograft Model

Global Preclinical CRO Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiology
Infectious Diseases
Metabolic Disorders
Others

Global Preclinical CRO Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical and Biotechnological Companies
Government and Academic Institutes
Medical Device Companies
Others

Global Preclinical CRO Market Size & CAGR (2026-2033)

North America (Service, Model, Application, End User)
- US
- Canada
Europe (Service, Model, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, Model, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, Model, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service, Model, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Charles River Laboratories International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Labcorp Drug Development (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Parexel International Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PPD (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syneos Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Crown Bioscience (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Envigo (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intertek Group plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SGS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MPI Research (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Worldwide Clinical Trials (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inotiv, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Biosys Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments